Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

An open letter written to vaccine manufacturer Bharat Biotech International Ltd and to the Indian Council of Medical Research ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Troriluzole failed a phase 3 trial in spinocerebellar ataxia in 2022. Based on talks with the FDA, Biohaven kept tracking ...

The jury is currently out on whether pathology giant Healius will be better off without its Lumus imaging business.

Swiss anti-aging biotech Rejuveron is seeking its rejuvenation as it morphs into Centenara Labs. | Swiss anti-aging biotech ...

Moleculin Biotech shares were up 12% to $2.65 after the company said it saw positive in vivo efficacy data of Annamycin in lung metastatic models of sarcoma. The stock is approaching its 52-week low ...

The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup ...

Moleculin Biotech said it saw positive in vivo efficacy data of Annamycin in orthotopic and experimental lung metastatic models of sarcoma. The clinical-stage pharmaceutical company saw the results in ...

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last ...

The biotechnology industry hopes the new Vigyan Dhara initiative of the Union government with a Rs. 10,000 crore outlay will result in better fund utilisation, and improve efficiency with its support ...

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...